We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Omeros Corp (OMER) NPV

Sell:$3.45 Buy:$3.46 Change: $0.04 (1.17%)
NASDAQ:0.02%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.45
Buy:$3.46
Change: $0.04 (1.17%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.45
Buy:$3.46
Change: $0.04 (1.17%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Omeros Corporation is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications.

Contact details

Address:
201 Elliott Avenue West
SEATTLE
98119
United States
Telephone:
+1 (206) 6765000
Website:
https://www.omeros.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OMER
ISIN:
US6821431029
Market cap:
$217.51 million
Shares in issue:
62.87 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Gregory Demopulos
    Chairman of the Board, President, Chief Executive Officer
  • Michael Jacobsen
    Vice President - Finance, Chief Accounting Officer, Treasurer
  • George Gaitanaris
    Vice President - Science, Chief Scientific Officer
  • Peter Cancelmo
    Vice President, General Counsel, Secretary
  • Peter Williams
    Vice President - Human Resources
  • Debra Bowes
    Vice President, Chief Business Development Officer
  • Nadia Dac
    Vice President, Chief Commercial Officer
  • Mariana Dimitrova
    Vice President - Chemistry, Manufacturing and Controls
  • Catherine Melfi
    Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
  • Tina Quinton
    Vice President - Patents

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.